VERU INC.
VERU · XNASCIK 863894fmd_1N2TGTHJ76ZJTE7QMYG3M3H9SVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2008 to Jun 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 22 | 14 | 16 | 32 | 43 | 61 | 39 | 16 | 17 | – |
| Cost of revenue | 9 | 7 | 7 | 10 | 12 | 13 | 9 | 9 | 11 | – |
| Gross profit | 13 | 7 | 9 | 22 | 31 | 48 | 31 | 8 | 6 | – |
| Research and development | 0 | 3 | 11 | 14 | 17 | 33 | 71 | 51 | 13 | 16 |
| Selling, general and administrative | 9 | 12 | 15 | 14 | 14 | 21 | 43 | 48 | 31 | – |
| Total operating expenses | 10 | 16 | 30 | 28 | 31 | 53 | 114 | 107 | 37 | 36 |
| Operating income | 3 | (8) | (21) | (6) | (15) | 13 | (83) | (94) | (36) | (25) |
| Interest expense | – | – | 3 | 5 | 5 | 5 | 4 | 2 | 1 | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | (2) | (6) | (5) | (9) | (0) | 1 | 1 | 9 |
| Income before taxes | 3 | (9) | (23) | (12) | (20) | 4 | (84) | (93) | – | – |
| Income tax expense | 2 | (2) | 1 | (0) | (1) | (3) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 0 | (7) | (24) | (12) | (19) | 7 | (84) | (93) | (35) | (16) |
| Net income | 0 | (7) | (24) | (12) | (19) | 7 | (84) | (93) | (38) | (23) |
| Net income to common shareholders | 0 | (9) | (24) | – | – | – | – | – | – | – |